• Products
  • Insights
  • Practice Management
  • Resources
  • About Us

Domestic Equity fund

Hartford Healthcare HLS Fund   


Key Documents
      Actions

      Domestic Equity fund

      Hartford Healthcare HLS Fund   
      Share Class - HLS IB (HBGHX)

      Effective 12/31/17, this Fund is closed to certain qualified pension and retirement plans.  For more information, please refer to the fund's statutory prospectus.

      Objective

      Seeks long-term capital appreciation.

      Overview

      A stock fund that invests in health care, a sector that is experiencing innovations and breakthroughs across multiple subsectors.

      Portfolio Management
      Senior Managing Director
      Global Industry Analyst
      3
      YRS
      MANAGING THIS FUND
      17
      YRS
      AT WELLINGTON MANAGEMENT
      19
      YRS
      EXPERIENCE IN THIS INDUSTRY
      Managing Director
      Global Industry Analyst
      2
      YRS
      MANAGING THIS FUND
      9
      YRS
      AT WELLINGTON MANAGEMENT
      17
      YRS
      EXPERIENCE IN THIS INDUSTRY
      Managing Director
      Global Industry Analyst
      2
      YRS
      MANAGING THIS FUND
      11
      YRS
      AT WELLINGTON MANAGEMENT
      25
      YRS
      EXPERIENCE IN THIS INDUSTRY

      The portfolio managers are supported by the full resources of Wellington.

      Performance

      PERFORMANCE %
       
      CUMULATIVE %
      (as of 2/29/2024)
      AVERAGE ANNUAL TOTAL RETURNS %
      (as of 2/29/2024)
      YTD 1YR 3YR 5YR 10YR SI
      Hartford Healthcare HLS IB 5.27 15.31 2.18 9.06 9.32 11.24
      Benchmark 6.06 14.98 9.32 11.15 11.24 ---
      Morningstar Health Category 5.27 11.02 -0.81 7.31 8.41 ---
       
      CUMULATIVE %
      (as of 12/31/2023)
      AVERAGE ANNUAL TOTAL RETURNS %
      (as of 12/31/2023)
      YTD 1YR 3YR 5YR 10YR SI
      Hartford Healthcare HLS IB 3.81 3.81 0.29 10.61 9.89 11.08
      Benchmark 1.92 1.92 7.15 11.24 11.32 ---
      Morningstar Health Category 3.22 3.22 -2.35 8.65 8.95 ---

      Performance data quoted represents past performance and does not guarantee future results. The investment return and principal value of an investment will fluctuate so that an investor's shares, when redeemed, may be worth more or less than their original cost. Current performance may be lower or higher than the performance data quoted. For more current performance information to the most recent month ended, please visit hartfordfunds.com.

      SI = Since Inception. Fund Inception: 05/01/2000

      Hartford Healthcare HLS Fund IB Share Morningstar Ratings
      Morningstar Medalist RatingTM
      2/29/2024

      Characteristics

      FUND ESSENTIALS
      Inception Date 05/01/2000
      Net Assets $141 million
      Total Operating Expenses 1.16%
      Morningstar Category Health
      Lipper Classification Global Health/Biotechnology Funds
      CUSIP 416528693
      Fund Number 2056
      FUND STATS
      # of Holdings
      100
      % in Equities
      99
      % in Foreign Equities
      14
      Beta (3 year)
      0.97
      R Squared (3 year)
      0.88
      Standard Deviation
      15.18%
      Turnover- (12/31/2023)
      28%
      Active Share
      47%
      Holdings Characteristics
      FUND S&P Composite 1500 Health Care Index
      Price/Earnings
      28.9x 18.5x
      Price/Book
      5.5x 4.9x
      EPS Growth Rate
      18.0% 14.4%
      Asset Weighted Market Cap (billions)
      $188.5 $235.5
      Return on Equity
      21.3% 32.2%
      Median Market Cap (billions)
      $10.5 $5.6
      Top Holdings (%)
      Eli Lilly & Co. 10.93
      UnitedHealth Group, Inc. 6.79
      Merck & Co., Inc. 6.37
      Danaher Corp. 3.90
      Stryker Corp. 2.83
      Boston Scientific Corp. 2.80
      HCA Healthcare, Inc. 2.51
      Thermo Fisher Scientific, Inc. 2.51
      AbbVie, Inc. 2.39
      Vertex Pharmaceuticals, Inc. 2.32
      Total Portfolio % 43.35
      Market Cap Distribution (%)

      Market Cap Header3

      Less than $2 billion 3
      $2 billion - $5 billion 7
      $5 billion - $10 billion 8
      Greater than $10 billion 82
      Not Classified 0
      Subsector Exposure
      Biopharma Large Cap 36
      Medical Technology 27
      Health Care Services 25
      Biopharma Mid Cap 9
      Biopharma Small Cap 3
      Biopharma Large Cap 34
      Medical Technology 27
      Health Care Services 26
      Biopharma Mid Cap 11
      Biopharma Small Cap 2
      Based on sub-adviser's classification of health care subsectors, which includes combining biotechnology and pharmaceuticals in terms of capitalization: biopharma small-cap, biopharma mid-cap, and biopharma large-cap. Excludes cash. May not total to 100% due to rounding.
      distributions and capital gains
      Distribution Date Distribution NAV ordinary income short term capital gains long term capital gains total distribution
      8/25/2023 13.84 $0.0384 $0.0000 $0.2095 $0.2479
      Past distributions are not indicative of future distributions.

      Fund Literature


      12/31/2023 - PDF (278 KB)
      Current quarterly commentary from our sub-adviser, Wellington Management, which includes a performance review, attribution, statistics, and positioning and outlook for the Fund.
      PDF (130 KB)
      A summary of a fund's full-length prospectus that provides key information potential investors should consider before making an investment decision.
      PDF (2 KB)
      An unaudited financial report, which includes a fund's financial statements. These reports are intended for shareholders and others who have reviewed the fund's prospectus.
      PDF (13 KB)
      A legal document that discloses essential information about a fund, including investment objectives, risks, fees, expenses, fund manager background and other information.
      PDF (2 KB)
      An audited financial report, which includes a fund's financial statements. These reports are intended for shareholders and others who have reviewed the fund's prospectus.
      PDF (13 KB)
      A document that supplements the fund's prospectus with additional information about the fund including its operations and risks.
      Important Risks: Investing involves risk, including the possible loss of principal. Security prices fluctuate in value depending on general market and economic conditions and the prospects of individual companies. • Risks of focusing investments on the healthcare related sector include regulatory and legal developments, changes in funding or subsidies, patent and intellectual property considerations, intense competitive pressures, rapid technological changes, long and costly process for obtaining product approval by government agencies, potential product obsolescence, rising cost of medical products and services, and price volatility risk. • Small- and mid-cap securities can have greater risks and volatility than large-cap securities. • Foreign investments may be more volatile and less liquid than U.S. investments and are subject to the risk of currency fluctuations and adverse political, economic and regulatory developments. These risks may be greater, and include additional risks, for investments in emerging markets.

      Hartford HLS Funds are distributed by Hartford Funds Distributors, LLC (HFD), Member FINRA. Advisory services are provided by Hartford Funds Management Company, LLC (HFMC). The Funds are sub-advised by Wellington Management Company LLP. HFMC and Wellington Management are SEC registered investment advisers. Hartford Funds refers to HFD and HFMC, which are not affiliated with any sub-adviser.

      3471888

      The material on this site is for informational and educational purposes only. The material should not be considered tax or legal advice and is not to be relied on as a forecast. The material is also not a recommendation or advice regarding any particular security, strategy or product. Hartford Funds does not represent that any products or strategies discussed are appropriate for any particular investor so investors should seek their own professional advice before investing. Hartford Funds does not serve as a fiduciary. Content is current as of the publication date or date indicated, and may be superseded by subsequent market and economic conditions.

      Investing involves risk, including the possible loss of principal. Investors should carefully consider a fund's investment objectives, risks, charges and expenses. This and other important information is contained in the mutual fund, or ETF summary prospectus and/or prospectus, which can be obtained from a financial professional and should be read carefully before investing.

      Mutual funds are distributed by Hartford Funds Distributors, LLC (HFD), Member FINRA|SIPC. ETFs are distributed by ALPS Distributors, Inc. (ALPS). Advisory services may be provided by Hartford Funds Management Company, LLC (HFMC) or its wholly owned subsidiary, Lattice Strategies LLC (Lattice). Certain funds are sub-advised by Wellington Management Company LLP and/or Schroder Investment Management North America Inc (SIMNA). Schroder Investment Management North America Ltd. (SIMNA Ltd) serves as a secondary sub-adviser to certain funds. HFMC, Lattice, Wellington Management, SIMNA, and SIMNA Ltd. are all SEC registered investment advisers. Hartford Funds refers to HFD, Lattice, and HFMC, which are not affiliated with any sub-adviser or ALPS. The funds and other products referred to on this Site may be offered and sold only to persons in the United States and its territories.

      © Copyright 2024 Hartford Funds Management Group, Inc. All Rights Reserved. Not FDIC Insured | No Bank Guarantee | May Lose Value